Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib a... by Landray, M, REVEAL Collaborative Group

Impact of new cardiovascular events on quality of life and hospital costs in people with cardiovascular disease in the United Kingdom and United States by Lui, JNM, Williams, C, Keng, MJ, Hopewell, JC, Sammons, E, Chen, F, Gray, A, Bowman, L, Landray, MJ, Mihaylova, B

Other Authors: “…REVEAL Collaborative Group…”

Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease by Sammons, E, Hopewell, JC, Chen, F, Stevens, W, Wallendszus, K, Valdes-Marquez, E, Dayanandan, R, Knott, C, Murphy, K, Wincott, E, Baxter, A, Goodenough, R, Lay, M, Hill, M, Macdonnell, S, Fabbri, G, Lucci, D, Fajardo-Moser, M, Brenner, S, Hao, D, Zhang, H, Liu, J, Wuhan, B, Mosegaard, S, Herrington, W, Wanner, C, Angermann, C, Ertl, G, Maggioni, A, Barter, P, Mihaylova, B, Mitchel, Y, Blaustein, R, Goto, S, Tobert, J, DeLucca, P, Chen, Y, Chen, Z, Gray, A, Haynes, R, Armitage, J, Baigent, C, Wiviott, S, Cannon, C, Braunwald, E, Collins, R, Bowman, L, Landray, M

Other Authors: “…HPS3/TIMI55-REVEAL Collaborative Group…”